AstraZeneca (AZN) Earns “Hold” Rating from Shore Capital
AstraZeneca (LON:AZN)‘s stock had its “hold” rating reaffirmed by equities researchers at Shore Capital in a note issued to investors on Friday.
AZN has been the subject of several other research reports. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a research note on Friday. Liberum Capital reiterated a “hold” rating on shares of AstraZeneca in a research note on Friday. HSBC set a GBX 4,860 ($63.50) price objective on shares of AstraZeneca and gave the company a “sell” rating in a research note on Wednesday, November 28th. Kepler Capital Markets reiterated a “buy” rating and issued a GBX 6,100 ($79.71) price objective on shares of AstraZeneca in a research note on Thursday, November 22nd. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research note on Monday, November 19th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of GBX 5,927.44 ($77.45).
Shares of LON AZN opened at GBX 6,007 ($78.49) on Friday. AstraZeneca has a 52-week low of GBX 4,260 ($55.66) and a 52-week high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: Why do companies issue stock splits?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.